On the 8th of August, 1988, several prominent doctors and surgeons believed that conventional drugs were lacking in potency and believed that only a quality drug will improve the welfare of mankind.

Concerned for their patients’ health and wellbeing, the founders decided to establish a state of the art pharmaceutical manufacturing facility to create drugs in accordance to their own strict specifications. As a result of such strong ideals and a passion for welfare, Fahrenheit was born. As such, the visions of our founders can be reflected in the company’s name, PT. Pratapa Nirmala. Adopted from ancient Sanskrit, Pratapa translates to glory while Nirmala means pure. In short, to achieve glory, we need to get customer respect and loyalty, and the only way to achieve this is to sell our products in its purest form, the highest possible quality.

Fahrenheit’s first manufacturing facility was constructed in a major industrial complex in Tangerang, West Java on two hectares of land. Its first commercial batch consisted of cardiovascular drugs and vitamins prepared in simple oral forms. Since then, the plant’s technology and facilities have been continuously upgraded several times to offer only the highest quality products.

In 1994, Fahrenheit expanded its manufacturing and added oral and injectable Cephalosporine to its lineup. Another expansion was completed in 1995 to accommodate the manufacturing of small volume parenteral (SVP) and ophthalmic products. Despite the economic crisis of 1998 in Asia, the company aggressively expanded its manufacturing capabilities to develop large volume parenteral products with a focus on antibiotics. Our investment in oral and injectable hormone contraceptive products bore fruit in 2004. A new facility was constructed to accommodate for increased demand of oral and injectable Cephalosporine in 2010.

By 2012, the company invested in a larger SVP plant complete with a lyophilized facility. We finished construction of a larger facility for LVP products in 2015 and we are currently building an additional plant for our oral dosage preparations due to be finished in 2017. All of Fahrenheit’s practices comply with the GMP International Standards to develop an assortment of ethical products for cardiovascular, hematopoietic, respiratory, metabolic, alimentary, genitourinary systems, antibiotics and vitamins from simple oral forms two injectable forms including IV solutions. With the company’s wide range of capabilities, it has positioned itself as a major branded generic manufacturing company in Indonesia focusing on specialty products.

PT. Fahrenheit Synthon Pharma (Joint Venture)

For the sake of achieving our vision to be a company that focuses on specialty pharmaceutical products, we have formed a joint venture company called PT. Fahrenheit Synthon Pharma with Synthon BV from the Netherlands. Synthon BV is uniquely established and is highly recognized as a vertically integrated company developing and manufacturing specialty products from active raw materials to its finished formulations. Our manufacturing facility is located at Kawasan Industri Milennium, Tangerang which will product high potent oral products used in the field of oncology.

With this company, this unique manufacturing capability will provide Fahrenheit with the opportunity to penetrate the fast growing specialty segment of oncology as well as neurology and urology segments. Together with Synthon BV, Farhenheit has the potential to become a market leader in the specialty segment. Our joint venture company will compete in the specialty segment which has been historically dominated by multinational companies and our job will be to provide alternative prescription medicine for medical doctors and Indonesian patients that has been approved by European standards.

As such, we will be able to reach our vision to be a company that produces specialty pharmaceutical products and our extended range of products will be able to cater to more patients as part of our mission.

In new markets, we aim to develop a strong formulation and manufacturing capabilities to establish ourselves as early generic players in the market.

In addition, we will increase our business development capabilities to identify new niche market segments. Fahrenheit plans to expand its influence internationally with other pharmaceutical industries, particularly on hospital and niche products. We will create strong bonds with our partners overseas in a way that is beneficial to our partners and to ourselves. Below are some examples as a result of our collaboration

“I do solemnly pledge that I will tell the doctor the truth, the whole truth, and nothing but the truth, that I will make no exaggerated claims of superiority or safety; that I will always give adequate assurance and proof that what I say about a product is true; that I will constantly remind myself that no mediation is 100% effective in all patients and that even a placebo may cause distressing side effect in some patients; and that the difference between the product I am detailing and the product the doctor has been using is much smaller in his eyes than in my own, and any exaggeration in this difference will only serve to confirm previous prescription writing habit. Professionalism belongs to every business level, from the chairman of the board to the operator of the manufacturing equipment. The job itself is not important; it’s how you do it that counts. There is only one way to take pride in what you do: “Do the best job you possibly can”. To do that you have to sort out your priority. By doing so you will be able to improve your skill for the sake of Fahrenheit growth”.

The medical representatives’ dedication to the above pledge, as well as their desire to promote high value medicine, contribute to the significant sales growth achieved in the recent years. Fahrenheit has enjoyed consistent sales growth due to our hard work in ensuring the highest quality in our products leading to a high level of respect and loyalty among our customers.

As a leading pharmaceutical company in Indonesia, Fahrenheit understands the importance of conducting market surveys to explore new opportunities, evaluate the market, assess customer needs, and study global marketing trends prior to the product launch. This approach ensures the most suitable selection of available resources in order to achieve the best rate of return and achieve our vision of becoming the leading pharmaceutical company in Indonesia focusing on specialty products.

With years of experience in medical training, our marketing team has successfully penetrated the specialty market which has been historically dominated by multinational companies. The team has always, and will continue to spread its influence through medical seminars, promotions, social media, and more. At present, Fahrenheit’s marketing network covers almost all of Indonesia, with 34 bases, 360 Medical Representatives, 146 Supervisors, 36 Regional Sales Managers and 6 Sales Managers. The company’s influence has also spread regionally, with exports to the Philippines, Thailand, Brunei, Timor Leste, Saudi Arabia, Ethiopia, Pakistan, Jordania, Malaysia.

In accordance to our vision and mission, we at Fahrenheit believe that our existence, as well as our future, depends entirely on our ability to consistently manufacture products of the highest quality. Therefore, we believe that effective total quality management is; aside from being a basic necessity, also a top priority.

Fahrenheit adheres to the following parameters in manufacturing: the drugs have to be completely safe, they have to be authentic and have the highest purity, and they should have a reputable and reliable efficacy. Fahrenheit has implemented total quality management procedures which adhere to the International GMP Standards and are coordinated from fully equipped, modern laboratories led by highly qualified pharmacists. In addition, the company implements and strictly carries out the ‘World Manufacturing Practice’ which ensures that quality is etched directly into its products.